Pdl biopharma, inc. (PDLI)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Gain (Loss) on Disposition of Assets

3,476

0

0

-

-

-

-

-

-

-

-

-

Cash flows from operating activities
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

-70,691

-68,859

110,701

63,659

332,795

322,244

-

-

-

-

-

-

Net income

-

-

-

-

-

-

264,530

211,669

199,389

91,874

189,660

68,387

Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of convertible notes conversion option and debt issuance costs

7,237

7,609

11,038

10,009

12,963

18,696

13,320

12,481

5,386

1,682

2,159

2,345

Accreted interest

79

-

-

-

-

-

-

-

-

-

-

-

Amortization of intangible assets

6,300

15,800

24,700

12,000

0

0

-

-

0

-

-

1,585

Amortization of right-of-use assets

886

-

-

-

-

-

-

-

-

-

-

-

Impairment of Intangible Assets, Finite-lived

22,490

152,330

0

0

-

-

-

-

-

-

-

-

Asset Impairment Charges

10,768

8,200

0

3,735

-

-

-

-

-

-

-

3,777

Goodwill, Impairment Loss

-

-

-

-

0

0

-

-

-

-

-

-

Change in fair value of acquired royalty rights

31,042

-85,256

-162,327

-16,196

-68,367

-44,927

5,637

0

-

-

-

-

Change in fair value of equity affiliate

31,641

-

-

-

-

-

-

-

-

-

-

-

Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Change in Unrealized Gain (Loss)

4,715

33

-49

-906

985

0

0

-

-

-

-

-

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

0

-41,631

349

-3,716

0

0

-

-

-

-

-

-

Amortization of non-recourse notes offering costs

-

-

-

-

-

-

-

1,226

4,533

7,238

1,256

-

Other amortization and depreciation

2,901

3,696

2,366

18

40

-134

-404

946

1,405

-

-

-

Gain (Loss) on Sale of Notes Receivable

-

-

-

-51,075

-3,979

0

0

-

-

-

-

-

Other amortization and depreciation expense

-

-

-

-

-

-

-

-

-

-

-

20,909

Gain (Loss) on Extinguishment of Debt

-8,430

0

0

-2,353

6,450

-6,143

0

0

-766

-17,648

1,518

-

Other amortization, depreciation and accretion of embedded derivative

-

-

-

-

-

-

-

-

-

330

991

-

Hedge ineffectiveness on foreign exchange contracts

-

-

-

-

-

5

11

257

0

-

-

-

Gain (Loss) on Sale of Investments

0

764

108

882

997

30

0

0

-

-

-

-

Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property

-

-

-

0

-

-

-

-

-

-

-

-

Stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

8,783

Loss on sale of assets, net

-

-

-

-

-

-

-

-

-

-

-

14,897

Loss on disposal of property and equipment

-1,200

-66

0

-

-

-

-

-

-

-

-

-220

Inventory Write-down

-300

-1,200

2,000

342

0

0

-

-

-

-

-

-

Provision for bad debts

-

-

-

0

0

-

-

-

-

-

-

-

Increase (Decrease) in Other Receivables

0

0

1,400

0

0

-

-

-

-

-

-

-

Business Combination, Bargain Purchase, Gain Recognized, Amount

0

0

9,309

0

0

-

-

-

-

-

-

-

Hedge ineffectiveness on foreign exchange contracts

-

-

-

-

-

-

-

-

-

0

-

-

Stock-based compensation expense

7,119

4,758

3,138

3,742

2,045

1,501

872

937

387

662

821

-

Tax benefit (expense) from stock-based compensation arrangements

-

-

-

-

-

-

-

-

-

12,818

64,140

19,720

Net excess tax benefit from stock-based compensation

-

-

-

-

-

-

22

27

0

-12,924

-70,610

19,317

Deferred Tax Expense from Stock Options Exercised

-

-

-

-

-

-

-

-

-120

-

-

-

Deferred taxes

-10,617

13,846

39,172

-10,676

17,251

-19,842

-999

11,338

31,217

-5,677

10,242

-

Changes in assets and liabilities:
Deferred income taxes

-

-

-

-

-

-

-

-

-

-

-

-21,909

Accounts receivable, net

-

-

-

-

-

-

-

-

-

-

-

-17,201

Interest receivable

-

-

-

-

-

-

-

-

-

-

-

-967

Accounts receivable

-8,195

-9,349

-11,008

34,120

0

0

-66

-234

131

-581

-12,450

12,490

Increase (Decrease) in Accounts and Other Receivables

-

-

-

6,000

-300

0

-

-

-

-

-

-

Prepaid and other current assets

-4,464

5,025

9,100

1,526

42

-2,126

-387

-5,233

199

-1,445

4,903

12,497

Accrued interest on notes receivable

0

0

-1,475

2,764

2,246

6,800

9,530

2,832

0

0

-

-

Inventory

21,923

9,508

-892

3,227

0

0

-

-

-

-

-

-

Other assets

156

2,120

1,400

757

865

63

-264

17

6,639

-182

-

-568

Accounts payable

4,191

-6,642

10,840

6,621

76

31

-787

546

-2,012

2,170

-1,347

-

Accrued legal settlement

-

-

-

-

-

-

-

27,500

37,500

-

-

-

Accrued legal settlement

-

-

-

-

-

-

-

-

-

65,000

-

-

Accounts payable

-

-

-

-

-

-

-

-

-

-

-

-7,176

Accrued liabilities

-9,341

-7,449

13,120

22,729

-1,048

4,343

-1,447

62

239

-26,229

-16,387

-32,350

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-

-

2,859

Increase (Decrease) in Deferred Revenue

-

-

-

-

-

-

-

-

-

-

-

23,670

Increase (Decrease) in Income Taxes Payable

1

-1,361

-3,346

1,352

79

3,293

0

0

-

-

-

-

Increase (Decrease) in Other Deferred Liability

-

-

-

-787

0

0

-

-

-

-

-

-

Other long-term liabilities

4,808

-462

-1,223

3,800

12,937

5,705

-2,131

-1,533

-26,939

27,500

-

-

Net cash provided by operating activities

-32,443

-13,425

40,624

101,718

301,465

292,281

269,745

212,506

169,782

184,300

186,954

80,149

Cash flows from investing activities
Purchase consideration paid in advance

-

-

-

-109,938

0

0

-

-

-

-

-

-

Purchases of investments

0

0

23,213

22,952

0

1,750

9,875

29,898

74,744

46,668

-

-

Payments to Acquire Investments

-

-

-

-

-

-

-

-

-

-

-

15,000

Payments to Acquire Other Investments

60,000

0

0

75,000

0

0

-

-

-

-

-

-

Proceeds from Sale and Maturity of Other Investments

0

0

75,000

0

0

-

-

-

-

-

-

-

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements

0

-858

0

0

-

-

-

-

-

-

-

-

Proceeds from Sale of Intangible Assets

5,000

0

0

-

-

-

-

-

-

-

-

-

Maturities of investments

0

4,116

39,956

4,680

1,947

3,530

43,780

50,831

50,696

9,772

15,000

-

Purchase of royalty rights

0

20,000

0

59,500

115,000

81,100

241,314

0

-

-

-

-

Increase (Decrease) in Restricted Cash

-

-

-

-

-

-

-

-

-

-

-3,469

-24,805

Payments for (Proceeds from) Productive Assets

-79,272

-77,969

-107,253

-72,582

-43,407

-102,460

0

0

-

-

-

-

Payments to Acquire Intangible Assets

1,700

0

0

-

-

-

-

-

0

-

-

-

Sale of commercial assets

-

-

-

-

-

-

-

-

-

-

-

272,945

Proceeds from Sale of Productive Assets

0

0

108,169

0

0

-

-

-

-

-

-

236,560

Issuance of notes receivable

-

-

-

9,010

35,235

230,000

148,708

97,590

0

0

-

-

Proceeds from Sale and Collection of Notes Receivable

0

0

144,829

54,653

25,242

-

-

-

-

-

-

-

Repayment of notes receivable

0

0

8,190

0

0

68,800

59,279

5,000

0

0

-

-

Purchase of property and equipment

763

4,523

1,297

25

9

49

2

51

0

0

39

3,273

Maturities of investments

-

-

-

-

-

-

-

-

-

-

-

70,778

Net cash provided by/(used in) investing activities

21,809

56,704

458,887

-144,510

-79,648

-138,109

-296,840

-71,708

-24,048

-36,896

18,430

586,815

Cash flows from financing activities
Repayments of Unsecured Debt

-

-

-

25,000

-

-

-

-

-

-

-

-

Cash payment for repurchase of convertible notes

97,889

-

-

-

-

-

-

-

-

-

-

-

Retirement of convertible notes

-

-

-

-

-

-

-

-

133,851

108,247

69,953

-

Repayments of Secured Debt

-

-

-

-

-

-

-

93,370

110,900

95,730

-

-

Other Payments to Acquire Businesses

0

0

87,007

0

0

-

-

-

-

-

-

-

Payments for Repurchase of Convertible Preferred Stock

-

0

0

120,000

220,397

56,191

0

0

-

-

-

-

Proceeds from term loan

-

-

-

-

100,000

0

74,169

0

0

-

-

-

Repayments of Notes Payable

0

126,447

0

0

75,000

75,000

0

0

-

-

-

-

Payment of debt issuance costs

7,451

0

0

3,204

607

9,825

0

845

0

0

-

-

Net proceeds from the issuance of convertible notes

-

-

-

150,000

0

300,000

0

0

149,712

82,039

-

-

Net receipts for capped call transactions

3,025

0

0

-14,400

0

-30,951

0

0

-20,765

-

-

-

Payment of contingent consideration

1,071

-

-

-

-

-

-

-

-

-

-

-

Proceeds from Noncontrolling Interests

-

0

0

250

0

0

-

-

-

-

-

-

Cash paid for purchase of noncontrolling interest

0

0

2,170

0

0

-

-

-

-

-

-

-

Repurchase of Company common stock

86,898

49,109

30,000

0

0

-

-

-

-

-

-

-

Net proceeds from the issuance of non-recourse notes

-

-

-

-

-

-

-

-

-

-

285,746

-

Purchase of call options

-

-

-

-

-

-

-

-

-

0

-

-

Proceeds from issuance of warrants

-

-

-

-

-

11,427

0

0

10,868

0

-

-

Cash distribution to Facet Biotech Corporation

-

-

-

-

-

-

-

-

-

-

-

-405,968

Proceeds from issuance of common stock, net of cancellations

-

-

-

-

-

-

-

-

-

-

-

15,390

Payments of Dividends

9

48

222

16,583

98,307

96,557

84,006

83,942

83,828

130,043

319,020

506,612

Net settlement of stock-based compensation awards

-212

-351

0

0

-

-

22

27

0

12,924

70,610

19,317

Proceeds from issuance of common stock, net of cancellations

-

-

-

-

-

-

-

-

-

-

1,402

-

Payments of other long-term debt

-

-

-

-

-

-

-

-

-

-

-

667

Net cash used in financing activities

-190,505

-175,955

-119,399

-28,937

-294,311

42,903

-9,815

-178,130

-188,764

-239,057

-31,215

-878,540

Net increase/(decrease) in cash and cash equivalents

-201,139

-132,676

380,112

-71,729

-72,494

197,075

-36,910

-37,332

-43,030

-91,653

174,169

-211,576

Supplemental cash flow information
Cash (refunded) paid for income taxes

-2,689

3,805

43,366

50,000

168,000

189,000

139,000

99,000

83,000

69,000

29,258

-

Conversion of convertible notes

-

-

-

-

-

-

-

-

-

111,680

-

-

Cash paid for interest

4,265

6,654

9,286

-

-

-

-

-

-

-

-

11,874

Exchange of debt

-

0

0

-

-

-

-

-

-

-

-

-

Stock Issued

45,901

0

0

-

-

-

-

-

-

-

-

-

Supplemental disclosures of non-cash financing activities
Assets held for sale reclassified from other assets to intangibles

0

1,811

0

0

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

11,410

16,987

18,439

10,997

15,754

25,627

40,622

11,552

-

Other Significant Noncash Transaction, Value of Consideration Given

-

-

-

-

9,794

171,879

0

0

-

-

-

-

Noncash or Part Noncash Acquisition, Value of Assets Acquired

-

-

-

2,342

-

-

-

-

-

-

-

-

Noncash or Part Noncash Acquisition, Other Liabilities Assumed

-

-

-

87,007

-

-

-

-

-

-

-

-

Noncash or Part Noncash Acquisition, Value of Liabilities Assumed

-

-

-

47,360

-

-

-

-

-

-

-

-

Asset held for sale reclassified from notes receivable to other assets

0

0

10,000

0

-

-

-

-

-

-

-

-

Extinguishment of Debt, Amount

0

0

43,909

0

-

-

-

-

-

-

-

-

Cash paid during the year for income taxes

-

-

-

-

-

-

-

-

-

-

-

8,525

Transfer of assets, net of liabilities, to Facet Biotech Corporation

-

-

-

-

-

-

-

-

-

-

-

49,651

Guarantee issued in connection with the Spin-Off (Note 17)

-

-

-

-

-

-

-

-

-

-

-

10,700